Literature DB >> 8940074

The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells.

B D Cohen1, P A Kiener, J M Green, L Foy, H P Fell, K Zhang.   

Abstract

A collection of cell lines expressing each human epidermal growth factor receptor (HER) family member alone or in all pairwise combinations in a clone of NIH3T3 cells (3T3-7d) devoid of detectable epidermal growth factor receptor family members has been generated. Transformation, as measured by growth in soft agar, occurred only in the presence of appropriate ligand and only in cells expressing two different HER family members. Transfection of oncogenic neu (Tneu), conferred ligand-independent transformation only in cells which co-expressed HER1, HER3, or HER4, but not when expressed alone or with HER2. Cell lines were also tested for their ability to form tumors in animals. None of the cell lines expressing single HER family members was able to form tumors in animals with the exception of HER1, which was weakly tumorigenic. Although unable to form tumors when expressed alone, HER2 was tumorigenic when expressed with HER1 or HER3, but not HER4. Of all complexes analyzed, cells expressing HER1 + HER2 were the most aggressive. The relationship between HER1 activation, intracellular calcium fluxes, and phospholipase Cgamma1 activation is well established. We found that activation of HER1 was required for the induction of a calcium flux and the phosphorylation of phospholipase Cgamma1. These activities were independent of, and unaffected by, the co-expression of any other family member. Further, heregulin stimulation of all cell lines including those containing HER1 did not demonstrate any effect on intracellular calcium levels or phospholipase Cgamma1 phosphorylation. This demonstrates that heregulin induced cellular transformation by activating HER3- and HER4-containing complexes does not require the activation of either phospholipase Cgamma1 or the mobilization of intracellular calcium.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940074     DOI: 10.1074/jbc.271.48.30897

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.

Authors:  H Waterman; I Alroy; S Strano; R Seger; Y Yarden
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

Review 2.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

3.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Authors:  A E Lenferink; J F Simpson; L K Shawver; R J Coffey; J T Forbes; C L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

4.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

Authors:  L N Klapper; S Glathe; N Vaisman; N E Hynes; G C Andrews; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.

Authors:  Aimee K Bence; Eric B Anderson; Maqbool A Halepota; Michael A Doukas; Phillip A DeSimone; George A Davis; Deborah A Smith; Kevin M Koch; Andrew G Stead; Steve Mangum; Carolyn J Bowen; Neil L Spector; Showchien Hsieh; Val R Adams
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

6.  Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection.

Authors:  Thiagarajan Venkataraman; Christopher M Coleman; Matthew B Frieman
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

7.  ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.

Authors:  M A Olayioye; D Graus-Porta; R R Beerli; J Rohrer; B Gay; N E Hynes
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

Review 8.  Role of ErbB4 in breast cancer.

Authors:  Maria Sundvall; Kristiina Iljin; Sami Kilpinen; Henri Sara; Olli-Pekka Kallioniemi; Klaus Elenius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

9.  Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.

Authors:  A E Lenferink; R Pinkas-Kramarski; M L van de Poll; M J van Vugt; L N Klapper; E Tzahar; H Waterman; M Sela; E J van Zoelen; Y Yarden
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

10.  Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response.

Authors:  Harish Shankaran; H Steven Wiley; Haluk Resat
Journal:  Biophys J       Date:  2006-03-13       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.